Coherus Oncology (CHRS) Change in Inventory (2018 - 2026)

Coherus Oncology (CHRS) has 9 years of Change in Inventory data on file, last reported at $11.3 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Inventory fell 49.15% year-over-year to $11.3 million; the trailing twelve-month figure through Mar 2026 stood at $6.2 million (down 85.55% YoY), and the FY2025 full-year result was $17.1 million, down 46.46% from the prior year.
• Change in Inventory climbed to $11.3 million in Q1 2026, from $1.1 million in the prior quarter.
• In the past five years, Change in Inventory ranged from a high of $23.4 million in Q3 2022 to a low of -$3.8 million in Q2 2025.
• A 5-year average of $9.1 million and a median of $9.8 million in 2022 frame the typical range for Change in Inventory.
• Across the five-year window, Change in Inventory soared 443.63% in 2022 and sank 153.08% in 2025, its largest moves.
• Tracing CHRS's Change in Inventory over 5 years: stood at $9.8 million in 2022, then climbed by 20.44% to $11.8 million in 2023, then sank by 45.28% to $6.5 million in 2024, then plunged by 82.74% to $1.1 million in 2025, then soared by 915.44% to $11.3 million in 2026.
• Business Quant data shows CHRS's Change in Inventory at $11.3 million in Q1 2026, $1.1 million in Q4 2025, and -$2.5 million in Q3 2025.